Studies in preclinical NSCLC models have demonstrated that inhibition of CD47 using genetic or pharmacologic approaches impairs malignant phenotypes including tumor growth and immune escape, metastasis, stemness, and drug resistance. This evidence concerns the gene CD47 and non-small cell lung carcinoma.